Azenta's earnings call reflects a mix of strong operational and financial performance in core segments and successful transformation initiatives, but also highlights challenges in specific areas like B Medical and certain genomic services. The sentiment is cautiously optimistic with a strategic focus on growth and efficiency, yet tempered by macroeconomic uncertainties.

Company Guidance

During Azenta's Q4 2024 earnings call, the company provided guidance for fiscal year 2025, excluding B Medical, which they plan to sell. The guidance anticipates organic revenue growth of 3% to 5% year-over-year, with Multiomics expected to grow in the low single digits and Sample Management Solutions (SMS) in the mid-single digits. The company aims to expand its adjusted EBITDA margin by approximately 300 basis points, following a successful expansion of 550 basis points in Q4 2024. Notably, Azenta's revenue for fiscal 2024 was $656 million, down 2% organically from the previous year, and Q4 revenue was $170 million, down 2% organically. The company's strategic focus for 2025 includes portfolio optimization, operational excellence, and value-enhancing capital allocation, with an emphasis on driving core revenue growth, margin expansion, and cost structure optimization.

Positive Revenue Performance

Azenta delivered strong Q4 results with $170 million in revenue, despite a challenging market. SMS and Multiomics combined grew 5% organically year-over-year, with notable growth in cryogenic stores (67%) and consumables and instruments (14%).

Successful Transformation Initiatives

Azenta made significant progress under the Ascend 2026 program, impacting 16 sites for rationalization and reducing core IT systems from 13 to 8, contributing to a 300 basis point expansion in adjusted EBITDA margin for the year.

Strong Growth in Multiomics Segment

Multiomics segment revenue grew 8% year-over-year, with Next Generation Sequencing showing a 25% increase. The business in China grew organically by 6%.

Financial Efficiency and Shareholder Returns

Azenta returned $249 million to shareholders through share repurchases, completing a $1.5 billion program, and ended the quarter with $522 million in cash and no outstanding debt.

New Leadership and Strategic Focus

Appointment of Lawrence Lin as CFO and a focus on operational excellence and portfolio optimization, including the decision to sell B Medical Systems.

---

Azenta (AZTA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZTA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 11, 2025	2025 (Q1)	0.05 / -	0.02	―	―	―
Nov 12, 2024	2024 (Q4)	0.10 / 0.18	0.13	38.46% (+0.05)
Aug 06, 2024	2024 (Q3)	0.08 / 0.16	0.13	23.08% (+0.03)
May 08, 2024	2024 (Q2)	0.02 / 0.05	-0.06	183.33% (+0.11)
Feb 07, 2024	2024 (Q1)	-0.03 / 0.02	0.12	-83.33% (-0.10)
Nov 13, 2023	2023 (Q4)	0.02 / 0.13	0.16	-18.75% (-0.03)
Aug 08, 2023	2023 (Q3)	-0.03 / 0.13	0.12	8.33% (+0.01)
May 09, 2023	2023 (Q2)	-0.02 / -0.06	0.12	-150.00% (-0.18)
Feb 08, 2023	2023 (Q1)	0.10 / 0.12	0.12	0.00% (0.00)
Nov 14, 2022	2022 (Q4)	0.07 / 0.16	0.12	33.33% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AZTA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$45.99	$44.51	-3.22%
Aug 06, 2024	$58.34	$53.13	-8.93%
May 08, 2024	$54.07	$52.51	-2.89%
Feb 07, 2024	$65.05	$64.04	-1.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---